Page 224 - Quantitative Imaging of Small Tumours with Positron Emission Tomography

References 1. Cysouw MCF, Kramer GM, Hoekstra OS, et al. Accuracy and Precision of Partial-Volume Correction in Oncological PET/CT Studies. J Nucl Med. 2016;57:1642-1649. 2. Boellaard R, Delgado-Bolton R, Oyen WJ, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328-354. 3. Teo BK, Seo Y, Bacharach SL, et al. Partial-volume correction in PET: validation of an iterative postreconstruction method with phantom and patient data. J Nucl Med. 2007;48:802-810. 4. Tohka J, Reilhac A. Deconvolution-based partial volume correction in Raclopride-PET and Monte Carlo comparison to MR-based method. Neuroimage. 2008;39:1570-1584. 5. Kaalep A, Sera T, Rijnsdorp S, et al. Feasibility of state of the art PET/CT systems performance harmonisation. Eur J Nucl Med Mol Imaging. 2018;45:1344-1361. 6. Boussion N, Cheze Le Rest C, Hatt M, Visvikis D. Incorporation of wavelet-based denoising in iterative deconvolution for partial volume correction in whole-body PET imaging. Eur J Nucl Med Mol Imaging. 2009;36:1064-1075. 7. Cysouw MCF, Golla SVS, Frings V, et al. Partial-volume correction in dynamic PET-CT: effect on tumor kinetic parameter estimation and validation of simplified metrics. EJNMMI Res. 2019;9:12. 8. Lammertsma AA. Forward to the Past: The Case for Quantitative PET Imaging. J Nucl Med. 2017;58:1019-1024. 9. Verwer EE, Oprea-Lager DE, van den Eertwegh AJ, et al. Quantification of 18F-fluorocholine kinetics in patients with prostate cancer. J Nucl Med. 2015;56:365-371. 10. Kramer GM, Yaqub M, Vargas HA, et al. Assessment of Simplified Methods for Quantification of (18)F-FDHT Uptake in Patients with Metastatic Castration-Resistant Prostate Cancer. J Nucl Med. 2019;60:1221-1227. 11. Jansen BHE, Yaqub M, Voortman J, et al. Simplified Methods for Quantification of (18)F-DCFPyL Uptake in Patients with Prostate Cancer. J Nucl Med. 2019. 12. Christian BT, Vandehey NT, Floberg JM, Mistretta CA. Dynamic PET denoising with HYPR processing. J Nucl Med. 2010;51:1147-1154. 13. Golla SSV, Lubberink M, van Berckel BNM, Lammertsma AA, Boellaard R. Partial volume correction of brain PET studies using iterative deconvolution in combination with HYPR denoising. EJNMMI Res. 2017;7:36. 14. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50 Suppl 1:122S-150S. 15. Mankoff DA, Katz SI. PET imaging for assessing tumor response to therapy. J Surg Oncol. 2018;118:362- 373. 16. Weber WA. Assessing tumor response to therapy. J Nucl Med. 2009;50 Suppl 1:1S-10S. 17. Vargas HA, Kramer GM, Scott AM, et al. Reproducibility and Repeatability of Semiquantitative (18) F-Fluorodihydrotestosterone Uptake Metrics in Castration-Resistant Prostate Cancer Metastases: A Prospective Multicenter Study. J Nucl Med. 2018;59:1516-1523. 18. Kolinger GD, Vallez Garcia D, Kramer GM, et al. Repeatability of [(18)F]FDG PET/CT total metabolic active tumour volume and total tumour burden in NSCLC patients. EJNMMI Res. 2019;9:14. 19. Kramer GM, Frings V, Hoetjes N, et al. Repeatability of Quantitative Whole-Body 18F-FDG PET/CT Uptake Measures as Function of Uptake Interval and Lesion Selection in Non-Small Cell Lung Cancer Patients. J Nucl Med. 2016;57:1343-1349. 11 20. Oprea-LagerDE,KramerG,vandeVenPM,etal.RepeatabilityofQuantitative18F-Fluoromethylcholine PET/CT Studies in Prostate Cancer. J Nucl Med. 2016;57:721-727. 21. van Velden FH, Kramer GM, Frings V, et al. Repeatability of Radiomic Features in Non-Small-Cell Lung Cancer [(18)F]FDG-PET/CT Studies: Impact of Reconstruction and Delineation. Mol Imaging Biol. 2016;18:788-795. 22. Beattie BJ, Smith-Jones PM, Jhanwar YS, et al. Pharmacokinetic assessment of the uptake of 16beta- 18F-fluoro-5alpha-dihydrotestosterone (FDHT) in prostate tumors as measured by PET. J Nucl Med. 2010;51:183-192. Summarizing discussion 223